|
Volumn 44, Issue 2, 1999, Pages 317-321
|
The utility of serial complete blood count monitoring in patients receiving radiation therapy for localized prostate cancer
|
Author keywords
Bone marrow toxicity; Complete blood counts; Radiotherapy toxicity
|
Indexed keywords
ANTIANDROGEN;
GONADORELIN AGONIST;
HEMOGLOBIN;
ADULT;
AGED;
ARTICLE;
BLOOD CELL COUNT;
CANCER HORMONE THERAPY;
CANCER RADIOTHERAPY;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DIAGNOSTIC VALUE;
HEALTH CARE COST;
HEMATOLOGIC DISEASE;
HEMOGLOBIN DETERMINATION;
HUMAN;
LEUKOCYTE COUNT;
MAJOR CLINICAL STUDY;
MALE;
PATIENT MONITORING;
PRIORITY JOURNAL;
PROGNOSIS;
PROSTATE CARCINOMA;
RISK FACTOR;
THROMBOCYTE COUNT;
TREATMENT INDICATION;
AGED;
AGED, 80 AND OVER;
BLOOD CELL COUNT;
COSTS AND COST ANALYSIS;
HEMOGLOBIN A;
HUMANS;
LEUKOCYTE COUNT;
MALE;
MIDDLE AGED;
PLATELET COUNT;
PROSTATIC NEOPLASMS;
RADIOTHERAPY DOSAGE;
|
EID: 0032911483
PISSN: 03603016
EISSN: None
Source Type: Journal
DOI: 10.1016/S0360-3016(99)00018-8 Document Type: Article |
Times cited : (21)
|
References (10)
|